B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

Publisher: La Merie Publishing
Pages: 39
Format: PDF
Product Line:
Brief Report
Product Code: LMBR0012
Release Date: August of 2016

500.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

The highly restricted expression of B-cell maturation antigen (BCMA) to plasma cells and its role in the survival and growth for multiple myeloma cells makes BCMA a good potential target for enhanced immunotherapeutic strategies. This report describes and analyzes the

  • Scientific rationale for BCMA-targeted therapies;
  • Preclinical proof-of-concept of BCMA blockade;
  • Clinical experience with BCMA-targeted therapies;
  • The competitive landscape of BCMA-targeted treatment modalities;
  • Profiles of anti-BCMA CAR T-cells, antibody-drug conjugate and T-cell redirecting bispecific antibodies:
  • Profiles of companies involved in develompent of anti-BCMA therapy candidates.

Especially activity-enhanced antibodies and cells such as antibody-drug conjugates (ADCs) and T-cell redirecting bispecific antibodies as well as chimeric antigen receptor (CAR) T-cells, respectively, will benefit from the high target selectivity of BCMA to avoid on-target, off-tumor toxicity. As a consequence, novel cellular and humoral BCMA-targeted treatment modalities have emerged and resulting product candidates entered first-in-human clinical evaluation. Further development candidates are undergoing IND-enabling studies.

 

 

B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

Table of Contents

1          Target Background

2          Target Antigen Expression Profile

3          Preclinical Proof-of-Concept

4          Clinical Indications & Treatment Options

5          Clinical Experience with BCMA-Targeted Treatment Modalities

6          Treatment Modalities & Competitive Landscape

7          Drug & Cell Therapy Candidate Profiles
7.1       CAR T-Cells
7.2       Antibody-Drug Conjugate (ADC)
7.3       T-Cell Redirecting Antibodies

8          Company Profiles

9          References

 



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top